Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $26.67

Pacira BioSciences, Inc. (NASDAQ:PCRX) has been given a consensus rating of “Hold” by the nine brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $26.67.

Several research firms have weighed in on PCRX. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price objective on shares of Pacira BioSciences in a report on Tuesday, April 8th. HC Wainwright upped their target price on Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday, April 8th. Barclays boosted their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th.

Institutional Trading of Pacira BioSciences

A number of hedge funds and other institutional investors have recently modified their holdings of PCRX. Sterling Capital Management LLC increased its holdings in Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after acquiring an additional 1,208 shares during the last quarter. Ancora Advisors LLC bought a new stake in Pacira BioSciences in the 4th quarter worth approximately $26,000. Caitlin John LLC raised its holdings in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after acquiring an additional 1,776 shares in the last quarter. Wealthquest Corp purchased a new position in shares of Pacira BioSciences in the first quarter valued at $59,000. Finally, Nisa Investment Advisors LLC raised its stake in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after purchasing an additional 2,749 shares in the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Stock Performance

NASDAQ PCRX opened at $26.75 on Tuesday. The company has a fifty day moving average of $24.61 and a 200-day moving average of $21.75. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences has a 52-week low of $11.16 and a 52-week high of $31.67. The company has a market capitalization of $1.24 billion, a P/E ratio of -13.18 and a beta of 0.71.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.